<DOC>
	<DOC>NCT00159731</DOC>
	<brief_summary>The purpose of this study is to 1) provide continued pregabalin treatment for 6 additional months to patients who have taken part in the placebo controlled study A0081060; and 2) find out if pregabalin is safe at a dose of 600 mg/day (taken twice a day)</brief_summary>
	<brief_title>Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Adults with Type 1 or 2 diabetes Patients must have pain in their lower legs or feet due to painful diabetic neuropathy that has lasted for at least 3 months Patients must not be in poor or unstable health.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>